News

Allergan bets on branded drugs
Enlarge image

M&AIreland

Allergan bets on branded drugs

28.07.2015 - Irish Allergan is bolstering its product pipeline with a takeover of CNS specialist Naurex. At the same time, the company is divesting its global generics business to Teva.

Naurex is a spin-out from the Northwestern University in Illinois, US that develops therapies for disorders of the central nervous system (CNS). Allergan will pay US$560m (€506m) for the US biopharma, US$460m (€416m) of which upfront, as well as milestone payments. In exchange, it can add Naurex’ anti-depression drug candidates to its pipeline. Both are targeted modulators of the N-methyl-D-aspartate receptor. Lead product rapastinel (GLYX-13) is a once-weekly intravenous molecule to treat depression that is set to start Phase III trials. NRX-1074, a next-generation drug candidate, has shown promise in intravenous form in Phase II and is being evaluated in Phase I when administered orally.

“The acquisition of Naurex is a great fit for Allergan and a compelling and exciting investment. We expect Naurex will enhance Allergan’s mental health portfolio and build on our strategy to lead in this important therapeutic area,” said Brent Saunders, CEO and President of Allergan.

The Dublin-based company also announced the divestment of its generics business to the world’s largest generics supplier Israeli company Teva Pharmaceutical Industries Ltd for US$40.5bn (€37bn). Subject of the deal is Allergan’s legacy – Actavis global generics business, including the US and international generic commercial units, third-party supplier Medis, global generic manufacturing operations, the global generic R&D unit, the international over-the-counter (OTC) commercial unit (excluding OTC eye care products) and some established international brands. Allergan will receive US$33.75bn (€30.5bn) in cash and US$6.75bn (€6.1bn) in Teva stock. In addition, Allergan retains 50 percent of Teva’s future economics from generic lenalidomide. “This transaction will accelerate Allergan’s evolution into a branded Growth Pharma leader, enable a sharpened focus on expanding and enhancing our global branded pharmaceutical business and strengthen our financial position to build on our proven track-record of value creation led by effective capital deployment,” said Brent Saunders, CEO and President of Allergan.

With part of the sale proceeds, the Irish company, formerly known as Actavis, means to pay off debt accumulated over the last few years, most recently with the US$66bn (€60bn) takeover of US company Allergan. Shortly after the acquisition, Actavis took on the name Allergan. 

After the announcements, Allergan’s stock price rose to a record high of more than US$325 (€294) per share.


© european-biotechnology-news.com/um

http://www.european-biotechnology-news.com/news/news/2015-03/allergan-sells-generics-buys-cns-drugs.html

Public marketGermanyFranceBelgiumFinlandDenmarkUK

24.07.2015 Biotech companies across Europe continue to raise cash on the public markets, generating €3bn in total financing proceedings in the first half of 2015. Compared to 2014, this is almost twice as much.

FinanceFrance

23.07.2015 US money keeps flowing into Europe's biotechs. As the race for the peanut allergy market heats up, NASDAQ listed French biotech DBV has announced the successful closing of US$281m (€256m) share offering for its allergy products.

BioplasticsFrance

21.07.2015 French biotech Deinove has launched a R&D programme to produce the versatile chemical intermediate muconic acid by using a designer variant of the Deinococcus bacteria.

BusinessFrance

16.07.2015 Sanofi has announced plans to restructure its business in five standalone global business units starting in January 2016. The goal is to promote growth and help the company launch a catalogue of new drugs over the next five years.

R&DUK

15.07.2015 GlaxoSmithKline (GSK) has become the first drugmaker to join the Francis Crick Institute. It is a consortium made up of six scientific and academic institutes to conduct research and drug development in the UK. The new institute is set to become a world-leading centre of biomedical research and innovation.

FundingUK

13.07.2015 UK drug developer ReNeuron has pulled in £68.4m (€96m) for its cell therapy pipeline for stroke and blindness treatments. Biotech guru Neil Woodford increases his fund’s stake in ReNeuron.

BusinessSweden

10.07.2015 Karolinska Development has slashed the reported value of its portfolio by almost half by revising its valuation model for early stage companies and divesting its shares in pain med maker Pharmanest.

M&AIreland

08.07.2015 Horizon Pharma plc. has set its sights on US-American speciality pharma company Depomed Inc. After getting nowhere with the rival’s board, Horizon has now launched a US$3bn hostile bid for the pain and CNS specialist.

BusinessIreland

07.07.2015 Irish pharma play Allergan plc. is boosting its eye care business by acquiring US-American medtech company Oculeve. Included in the deal are Oculeve’s dry eye disease development programmes.

© 2007-2015 BIOCOM

http://www.european-biotechnology-news.com/news/news.html?cHash=84e81f78a2ff57fea5f72d810e48c349&sort=asc

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • KAROLINSKA (S)12.95 SEK8.37%
  • IXICO (UK)35.50 GBP5.97%
  • SUMMIT (UK)4.03 GBP3.87%

FLOP

  • MEDIGENE (D)9.65 EUR-10.32%
  • SERODUS (N)3.08 NOK-8.88%
  • ZELTIA (E)3.69 EUR-8.44%

TOP

  • IXICO (UK)35.50 GBP57.8%
  • DBV TECHNOLOGIES (F)75.75 EUR43.9%
  • ADOCIA (F)88.67 EUR28.9%

FLOP

  • BIOTEST (D)25.26 EUR-64.3%
  • BIOTECH PHARMACON (N)9.44 NOK-47.6%
  • TRANSGENE (F)2.95 EUR-39.4%

TOP

  • ADOCIA (F)88.67 EUR532.9%
  • VERONA PHARMA (UK)4.88 GBP324.3%
  • FORMYCON (D)28.20 EUR305.8%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-87.5%
  • NEOVACS (F)1.05 EUR-69.6%
  • BIOTEST (D)25.26 EUR-69.3%

No liability assumed, Date: 27.07.2015